Paper20032971
CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
Stuhlmüller B and 9 others. Clin Pharmacol Ther, 2010. Cited by 67 papers, by iCite.
Cite this record
ConductScience Library. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Papers, record 20032971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20032971
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antirheumatic Agents | Major topic |
| Arthritis, Rheumatoid | Major topic |
| CD11c Antigen | Major topic |
| Transcription, Genetic | Major topic |
| Tumor Necrosis Factor-alpha | Major topic |
| Adalimumab | |
| Adult | |
| Aged | |
| Antibodies, Monoclonal, Humanized | |
| Biomarkers | |
| Cohort Studies | |
| Female | |
| Genetic Markers | |
| Humans | |
| Male | |
| Methotrexate | |
| Middle Aged | |
| Monocytes | |
| Predictive Value of Tests | |
| Protein Array Analysis | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02878161 | Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World" | Background |
Source ClinicalTrials.gov
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 67 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42539492 | Spatial transcriptomic analysis of kidney biopsies identifies activation of complement and SPP1 networks in Staphylococcus infection-associated glomerulonephritis. | Front Nephrol | 2026 | https://conductscience.org/library/papers/42539492 | PubMed |
| 41916981 | CXCR3 is associated with T-cell-induced heart damage in acute rheumatic fever. | Nat Commun | 2026 | https://conductscience.org/library/papers/41916981 | PubMed |
| 40428231 | Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40428231 | PubMed |
| 39346909 | Causal relationship, shared genes between rheumatoid arthritis and pulp and periapical disease: evidence from GWAS and transcriptome data. | Front Immunol | 2024 | https://conductscience.org/library/papers/39346909 | PubMed |
| 39058384 | miRNAs and NFKB1 and TRAF6 target genes: The initial functional study in CD14+ monocytes in rheumatoid arthritis patients. | Genet Mol Biol | 2024 | https://conductscience.org/library/papers/39058384 | PubMed |
| 38779469 | Towards Personalized Medicine in Rheumatoid Arthritis. | Open Access Rheumatol | 2024 | https://conductscience.org/library/papers/38779469 | PubMed |
| 38540800 | Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors. | Biomolecules | 2024 | https://conductscience.org/library/papers/38540800 | PubMed |
| 37509625 | DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis. | Biomedicines | 2023 | https://conductscience.org/library/papers/37509625 | PubMed |
| 36015273 | -Omic Approaches and Treatment Response in Rheumatoid Arthritis. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36015273 | PubMed |
| 36009355 | Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis. | Biomedicines | 2022 | https://conductscience.org/library/papers/36009355 | PubMed |
| 35003068 | Toward Overcoming Treatment Failure in Rheumatoid Arthritis. | Front Immunol | 2021 | https://conductscience.org/library/papers/35003068 | PubMed |
| 34148193 | A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study. | Rheumatol Ther | 2021 | https://conductscience.org/library/papers/34148193 | PubMed |
| 33397492 | Identification of differentially expressed genes, signaling pathways and immune infiltration in rheumatoid arthritis by integrated bioinformatics analysis. | Hereditas | 2021 | https://conductscience.org/library/papers/33397492 | PubMed |
| 32909363 | Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis. | Arthritis Rheumatol | 2021 | https://conductscience.org/library/papers/32909363 | PubMed |
| 32797404 | Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. | Rheumatol Ther | 2020 | https://conductscience.org/library/papers/32797404 | PubMed |
| 31647025 | Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor. | Arthritis Res Ther | 2019 | https://conductscience.org/library/papers/31647025 | PubMed |
| 31227791 | Association of ITGAX and ITGAM gene polymorphisms with susceptibility to IgA nephropathy. | J Hum Genet | 2019 | https://conductscience.org/library/papers/31227791 | PubMed |
| 30941119 | Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. | Front Immunol | 2019 | https://conductscience.org/library/papers/30941119 | PubMed |
| 30642076 | TNF-α Inhibitors Decrease Classical CD14hiCD16- Monocyte Subsets in Highly Active, Conventional Treatment Refractory Rheumatoid Arthritis and Ankylosing Spondylitis. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/30642076 | PubMed |
| 29520680 | [Relevance of big data for molecular diagnostics]. | Z Rheumatol | 2018 | https://conductscience.org/library/papers/29520680 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ITGAX | 3687 | PubTator's text mining | https://conductscience.org/library/genes/3687 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20032971
GET https://conductscience.org/api/papers/v1/20032971/cited_by?page=2